Skip to main content

Table 1 Patient characteristics based on recovery status of acute kidney injury (AKI)

From: Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population

Variable

Overall (n = 99)

AKI-recovered (n = 71)

AKI-unrecovered (n = 26)

Loss of follow-up (n = 2)

Male

70 (71)

51 (72)

18 (69)

1 (50)

Age ≥65

59 (60)

42 (59)

16 (62)

1 (50)

Smoking

48 (49)

37 (52)

10 (38)

1 (50)

Alcoholism

16 (16)

13 (18)

2 (8)

1 (50)

Malnutrition

39 (39)

24 (34)

14 (54)

1 (50)

Old TB history

3 (3)

2 (3)

1 (4)

0 (0)

Re-treatment of TB*

11 (11)

9 (13)

2 (8)

0 (0)

Co-morbidity

 CKD

30 (30)

21 (30)

9 (35)

0 (0)

 DM

25 (25)

15 (21)

10 (38)

0 (0)

 Malignancy

25 (25)

19 (27)

5 (19)

1 (50)

 Gout

15 (15)

10 (14)

5 (19)

0 (0)

 Autoimmune disease

6 (6)

4 (6)

2 (8)

0 (0)

 HIV

2 (2)

2 (3)

0 (0)

0 (0)

Sputum mycobacterial study

 AFB-positive

29 (29)

22 (31)

6 (23)

1 (50)

 Culture-positive

79 (80)

56 (79)

21 (81)

2 (100)

Presentations of AKI

 Rash

21 (21)

18 (25)

3 (12)

0 (0)

 Gastro-intestinal upset

17 (17)

14 (20)

3 (12)

0 (0)

 Fever

6 (6)

5 (7)

1 (3.8)

0 (0)

 Arthralgia

4 (4)

4 (6)

0 (0)

0 (0)

AKI stage

 Stage 1

83 (84)

63 (89)

19 (73)

1 (50)

 Stage 2

10 (10)

6 (8)

3 (12)

1 (50)

 Stage 3

6 (6)

2 (6)

4 (15)

0 (0)

 Onset of AKI after ATT (days)

44 [20–102]

40 [15–104]

50 [27–91]

73 [44–102]

 Management after AKI

 Hold rifampin

34 (34)

22 (31)

10 (38)

2 (100)

 Hold pyrazinamide#

35 (51)

24 (28)

11 (42)

0 (0)

 Re-challenge rifampin

21 (21)

14 (20)

7 (27)

NA

  1. Abbreviations: AFB acid-fast bacilli smear, AKI acute kidney injury, ATT anti-TB treatment, TB tuberculosis.
  2. Note: Data are either number (%) or median [inter-quartile range]. There was no statistically significant difference between the AKI-recovered and -unrecovered groups.
  3. *Re-treatment meant that AKI recurred after re-exposure to rifampin.
  4. #Only 69 patients received pyrazinamide-containing anti-TB regimen at the onset of AKI.